Zhixiang Shen

Frontline bortezomib, rituximab, cyclophosphamide, doxorubicin, and prednisone (VR-CAP) versus rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) in transplantation-ineligible patients with newly diagnosed mantle cell lymphoma: final overall survival results of a randomised, open-label, phase 3 study

Tadeusz Robak, Jie Jin, Halyna Pylypenko et al. · The Lancet Oncology · 2018 · 132 citations

Hematological Malignancy, Frontline Bortezomib, Lymphoid Neoplasia +13

Bosutinib efficacy and safety in chronic phase chronic myeloid leukemia after imatinib resistance or intolerance: Minimum 24‐month follow‐up

Carlo Gambacorti‐Passerini, Tim H. Brümmendorf, Dong‐Wook Kim et al. · American Journal of Hematology · 2014 · 116 citations · Full text

Imatinib Resistance, Hematological Malignancy, Chronic Myeloid Leukemia +15

Expanding Nilotinib Access in Clinical Trials (ENACT)

Franck E. Nicolini, Anna Turkina, Zhixiang Shen et al. · Cancer · 2011 · 68 citations · Full text

Effects of imatinib (Glivec) on the pharmacokinetics of metoprolol, a CYP2D6 substrate, in Chinese patients with chronic myelogenous leukaemia

Yanfeng Wang, Li Zhou, Catherine Dutreix et al. · British Journal of Clinical Pharmacology · 2008 · 54 citations · Full text

Rituximab in combination with CHOP chemotherapy for the treatment of diffuse large B cell lymphoma in China: a 10-year retrospective follow-up analysis of 437 cases from Shanghai Lymphoma Research Group

Xiaoyang Li, Zhao Liu, Junning Cao et al. · Annals of Hematology · 2011 · 52 citations

Hematological Malignancy, Lymphoid Neoplasia, Medicine +5